|Mr. Ronald A. Andrews Jr.||Pres, CEO & Director||801.84k||N/A||1960|
|Dr. Douglas T. Ross M.D., Ph.D.||Chief Science Officer||558.94k||N/A||1960|
|Mr. Mitchell S. Levine||Corp. Devel. Officer||480.71k||N/A||1960|
|Ms. Gisela A. Paulsen||COO & Pres||N/A||N/A||1966|
|Mr. Anish John||Chief Financial Officer||N/A||N/A||1970|
|Mr. James Liu||Controller & Principal Accounting Officer||N/A||N/A||1995|
|Dr. Ekkehard Schutz M.D., Ph.D.||Chief Technology Officer||N/A||N/A||N/A|
|Mr. William Annett||Advisor||N/A||N/A||1954|
|Mr. Robert S. Seitz||Head of Immune Oncology||N/A||N/A||1964|
|Dr. Michael D. West Ph.D.||Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.||N/A||N/A||1953|
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
OncoCyte Corporation’s ISS Governance QualityScore as of September 28, 2022 is 4. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 1; Compensation: 7.